Compare BNTC & CGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BNTC | CGC |
|---|---|---|
| Founded | 1995 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Pharmaceuticals and Biotechnology |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 344.4M | 299.0M |
| IPO Year | 2020 | 2023 |
| Metric | BNTC | CGC |
|---|---|---|
| Price | $9.20 | $0.57 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 3 |
| Target Price | ★ $23.29 | $1.77 |
| AVG Volume (30 Days) | 177.7K | ★ 2.5M |
| Earning Date | 11-24-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 6.67 | ★ 84.17 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $12,759,000.00 |
| Revenue This Year | N/A | $18.45 |
| Revenue Next Year | N/A | $7.42 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.89 | $0.58 |
| 52 Week High | $14.39 | $2.38 |
| Indicator | BNTC | CGC |
|---|---|---|
| Relative Strength Index (RSI) | 49.46 | 29.63 |
| Support Level | $8.14 | N/A |
| Resistance Level | $9.29 | $0.76 |
| Average True Range (ATR) | 0.64 | 0.04 |
| MACD | 0.16 | -0.00 |
| Stochastic Oscillator | 53.62 | 6.10 |
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on advancing novel genetic medicines. Its technology could provide a one-shot cure for a wide range of diseases that require strict, ongoing treatment regimens or have no effective treatment or only palliative care options. The Company is developing a silence-and-replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life-threatening genetic disorder. The company has a single operating segment, which is the business of discovery and development of therapeutic agents for the treatment of genetic disorders.
Canopy Growth Corp is a cannabis company that produces, distributes, and sells a diverse range of cannabis and cannabis-related products for adult-use and medical purposes under a portfolio of distinct brands in Canada. The Company supplies cannabis products in Canada, Europe, and Australia. It is focused on the medical and adult-use cannabis markets in Canada, offering a broad portfolio of brands and formats for medical cannabis patients and adult-use consumers. The Company operates through two reportable segments: Cannabis, which generates maximum revenue and includes the production, distribution, and sale of cannabis and cannabis-related products, and Storz & Bickel, which includes the production, distribution, and sale of vaporizers and accessories.